Vildagliptin recruits regulatory T cells in patientsundergoing primary percutaneous coronary interventio
Not Applicable
- Conditions
- MedDRA - Myocardial infarctionMedDRA - Diabetes
- Registration Number
- DRKS00014045
- Lead Sponsor
- Faculty of medicine - Tanta university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
diabetic patients with STE MI
Exclusion Criteria
Patients were excluded from the study if
they had any one of the following criteria: previous myocardial infarction,
previous PCI or coronary artery bypass intervention, were currently on DPP-
4 inhibitors, steroidal and non- steroidal anti-inflammatory drugs, has long
term immunosuppressive therapy, cancer and infectious diseases.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method What? <br>the addition of vild to<br>standard medical treatment of MIRI (myocardial ischaemia-reperfusion injury) could increase the effectiveness of it<br>through recruitment of CD4+CD25+ Treg cells.<br>How?<br>Through the assessment of percentage of changes in nitric oxide, ischemia modified albumin, highly sensitive C reactive protein and interferon gamma levels, myeloperoxidase activity, CD4 +CD25+ Treg cells count and Transforming growth factor-beta1 level in the studied groups.<br>When?<br>It is measured twice for each patient; reading 1 is baseline reading at time of admission before starting the treatment and reading 2 measured 72 hours after starting the medical treatment.
- Secondary Outcome Measures
Name Time Method